StocksRankings — AI Stock Picks & Rankings

AI Stock Picks — April 29, 2026

The 5 AI-selected stock picks for April 29, 2026 from StocksRankings — with full investment thesis, bull case, bear case, and key catalyst for each.

5 AI Stock Picks for April 29, 2026

  1. RTX — RTX Corporation [Winner on a Dip]
    RTX Corporation, a leading aerospace and defense contractor, stands to benefit from the ongoing Middle East conflict that has driven defense spending higher globally. Its Pratt & Whitney engine division supplies propulsion systems for the F-35 fighter, which is central to U.S. and allied military procurement, and the company reported $235.91B in market cap. The RSI of 11.8 signals extreme oversold conditions despite a 111% five-year performance, offering a favorable risk-reward entry.
    Key risk: A sudden de-escalation in Middle East tensions could delay or reduce new defense contract awards.
  2. GILD — Gilead Sciences [Winner on a Dip]
    Gilead Sciences, which specializes in antiviral and oncology therapies, is insulated from oil-driven inflation because pharmaceutical demand is inelastic regardless of energy prices. The company’s HIV franchise generated over $17B in annual revenue, and its $160.32B market cap reflects a strong balance sheet and recurring cash flow. The RSI of 17.9 and a five-year performance of 103% indicate the stock is oversold relative to its durable business model.
    Key risk: Pipeline setbacks or regulatory delays in late-stage oncology trials could impair future revenue growth.
  3. MCK — McKesson [Winner on a Dip]
    McKesson, the largest pharmaceutical distributor in the U.S., is unaffected by oil price shocks, as drug distribution volumes remain stable regardless of energy costs. The company’s scale advantage is clear, moving over one-third of all U.S. pharmaceuticals and supporting a 343% five-year performance. The RSI of 23.0 reflects a rare technical dislocation for a business with high recurring revenue and essential infrastructure.
    Key risk: A surprise Medicare drug-pricing expansion could compress McKesson’s distribution margins independent of volume.

See today's picks · full picks history · AI pick track record